SiBone (NASDAQ:SIBN) CFO Sells $330,885.36 in Stock

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 21,528 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $15.37, for a total transaction of $330,885.36. Following the sale, the chief financial officer owned 266,466 shares in the company, valued at $4,095,582.42. This represents a 7.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Friday, January 2nd, Anshul Maheshwari sold 5,229 shares of SiBone stock. The shares were sold at an average price of $19.64, for a total value of $102,697.56.
• On Thursday, December 18th, Anshul Maheshwari sold 18,542 shares of SiBone stock. The shares were sold at an average price of $20.15, for a total value of $373,621.30.
• On Tuesday, November 25th, Anshul Maheshwari sold 100 shares of SiBone stock. The stock was sold at an average price of $20.00, for a total value of $2,000.00.
• On Friday, November 21st, Anshul Maheshwari sold 1,200 shares of SiBone stock. The stock was sold at an average price of $20.01, for a total value of $24,012.00.

SiBone Stock Performance

NASDAQ:SIBN opened at $15.48 on Friday. SiBone has a twelve month low of $12.49 and a twelve month high of $21.89. The company has a quick ratio of 6.62, a current ratio of 7.97 and a debt-to-equity ratio of 0.21. The stock’s 50-day simple moving average is $17.84 and its 200 day simple moving average is $16.83. The firm has a market capitalization of $671.68 million, a PE ratio of -30.35 and a beta of 0.69.

Analyst Ratings Changes

SIBN has been the subject of a number of research reports. Morgan Stanley raised their price objective on shares of SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Canaccord Genuity Group upped their price target on shares of SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Needham & Company LLC raised their price target on shares of SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Truist Financial boosted their price objective on shares of SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SiBone in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $24.33.

Hedge Funds Weigh In On SiBone

Hedge funds have recently bought and sold shares of the company. Y Intercept Hong Kong Ltd lifted its stake in shares of SiBone by 337.7% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 83,369 shares of the company’s stock valued at $1,227,000 after purchasing an additional 64,322 shares during the period. Assenagon Asset Management S.A. acquired a new stake in SiBone during the third quarter worth approximately $3,297,000. Impax Asset Management Group plc increased its holdings in SiBone by 48.2% in the third quarter. Impax Asset Management Group plc now owns 1,025,010 shares of the company’s stock worth $15,088,000 after purchasing an additional 333,249 shares in the last quarter. Divisadero Street Capital Management LP lifted its stake in SiBone by 17.8% in the second quarter. Divisadero Street Capital Management LP now owns 339,791 shares of the company’s stock valued at $6,395,000 after buying an additional 51,363 shares during the period. Finally, Peregrine Capital Management LLC acquired a new position in SiBone in the second quarter valued at approximately $6,664,000. Institutional investors own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.